PSTV Plus Therapeutics Inc
Price (delayed)
$0.8902
Market cap
$15.13M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.95
Enterprise value
$18.42M
Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform
Highlights
The EPS has surged by 54% year-on-year and by 14% since the previous quarter
PSTV's debt is down by 19% year-on-year
The equity has dropped by 73% since the previous quarter
The quick ratio has plunged by 66% YoY and by 33% from the previous quarter
Key stats
What are the main financial stats of PSTV
Market
Valuations
Earnings
Shares outstanding
17M
Market cap
$15.13M
Enterprise value
$18.42M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.16
Revenue
$5.82M
Gross profit
$5.82M
Operating income
-$14.7M
Net income
-$12.98M
EBIT
-$9.25M
EBITDA
-$8.4M
Free cash flow
-$10.7M
Per share
Balance sheet
Liquidity
EPS
-$1.95
EPS diluted
-$2.34
Free cash flow per share
-$1.61
Book value per share
-$1.52
Revenue per share
$0.88
TBVPS
$0.87
Total assets
$6.63M
Total liabilities
$15.58M
Debt
$3.37M
Equity
-$8.95M
Working capital
-$10.29M
Debt to equity
-0.38
Current ratio
0.34
Quick ratio
0.27
Net debt/EBITDA
-0.39
Margins
Efficiency
Dividend
EBITDA margin
-144.3%
Gross margin
100%
Net margin
-222.8%
Operating margin
-252.3%
Return on assets
-170.5%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-158.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PSTV stock price
How has the Plus Therapeutics stock price performed over time
Intraday
-12.73%
1 week
-39.44%
1 month
22.79%
1 year
-52.4%
YTD
-22.59%
QTD
-6.3%
Financial performance
How have Plus Therapeutics's revenue and profit performed over time
Revenue
$5.82M
Gross profit
$5.82M
Operating income
-$14.7M
Net income
-$12.98M
Gross margin
100%
Net margin
-222.8%
Plus Therapeutics's gross profit has increased by 19% YoY
PSTV's revenue is up by 19% YoY
PSTV's net margin is up by 18% year-on-year
The operating income is down by 10% YoY
Growth
What is Plus Therapeutics's growth rate over time
Valuation
What is Plus Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.16
The EPS has surged by 54% year-on-year and by 14% since the previous quarter
The equity has dropped by 73% since the previous quarter
The P/S is 28% below the last 4 quarters average of 1.6
PSTV's revenue is up by 19% YoY
Efficiency
How efficient is Plus Therapeutics business performance
The ROA has plunged by 75% YoY and by 16% from the previous quarter
The return on sales is up by 40% year-on-year
Dividends
What is PSTV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PSTV.
Financial health
How did Plus Therapeutics financials performed over time
Plus Therapeutics's total assets is 57% lower than its total liabilities
The quick ratio has plunged by 66% YoY and by 33% from the previous quarter
Plus Therapeutics's current ratio has plunged by 63% YoY and by 23% from the previous quarter
PSTV's debt is 138% greater than its equity
The debt to equity has surged by 88% year-on-year and by 42% since the previous quarter
The equity has dropped by 73% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.